Početna › Akutna mijeloična leukemija › Texas
Kliničke studije za Akutna mijeloična leukemija u državi Texas
94 studija za Akutna mijeloična leukemija traži sudionike na lokacijama u državi Texas.
Gradovi u državi Texas
- Houston85 studija
- Dallas21 studija
- San Antonio5 studija
- Austin5 studija
- Fort Worth4 studija
- Corpus Christi3 studija
Službeni tekst studije (engleski)
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- The University of Texas MD Anderson Cancer Center /ID# 279402, Houston
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07581002Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
U tijeku regrutacijaOpažajna studija
Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 12 do 78 godina · Oba spola · Ažurirano 29. ruj 2026. · NCT03802695Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
U tijeku regrutacijaFaza 2
Od 18 do 59 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Baylor University Medical Center, Dallas
- Houston Methodist Cancer Center, Houston
- MD Anderson Cancer Center, Houston
- i još 2
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05564390Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT03629171A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06548230Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Houston
U tijeku regrutacijaFaza 3
Od 12 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07211958Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT03874052Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT03661307A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2Zdravi dobrovoljci dobrodošli
Od 12 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT05360160Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT06317649Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
- The University of Texas M. D. Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT06769490Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT03214562A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT06284486Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 1 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT03630991Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
- MD Anderson, Houston
U tijeku regrutacijaFaza 1
Od 12 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT06786533A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- i još 9
U tijeku regrutacijaFaza 3
6 Months – 21 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT04293562Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
U tijeku regrutacijaFaza 1
Do 75 godina · Oba spola · Ažurirano 16. ruj 2026. · NCT06345027Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT06824168(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT04996875Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT03471260Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT03683433A Study of BGB-11417 in Participants With Myeloid Malignancies
- Md Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT04771130A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
- The University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06616636A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06969430A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Children's Medical Center Dallas /ID# 275930, Dallas
U tijeku regrutacijaFaza 1
6 Months – 17 Years · Oba spola · Ažurirano 9. ruj 2026. · NCT07306832ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT05010122Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- i još 1
U tijeku regrutacijaFaza 3
Od 1 do 25 godina · Oba spola · Ažurirano 4. ruj 2026. · NCT07022678Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT03383575A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 2 do 18 godina · Oba spola · Ažurirano 4. ruj 2026. · NCT06191978Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Baylor Scott & White Health, Dallas
- MD Anderson, Houston
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT04588922Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Dallas TX-SOUTHWESTERN, Dallas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT06652438CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- The University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 do 85 godina · Oba spola · Ažurirano 26. kol 2026. · NCT06834282CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT04493164Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT06533761Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
- The University of Texas M. D. Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT06811233The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- i još 10
U tijeku regrutacijaFaza 1/2
Do 22 godina · Oba spola · Ažurirano 25. kol 2026. · NCT04726241Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.